Introduction
Gangliosides are complex glycosphingolipids that are ubiquitous components of mammalian cell membranes. Alterations in ganglioside composition have been associated with cell proliferation and differentiation [for review see (1) ]. One mechanism by which gangliosides may exert their effects on proliferation and differentiation is through modulation of tyrosine kinase growth factor receptors (2). Gangliosides have been shown to regulate the activity of epidermal growth factor receptor (EGFR 1 )(3), platelet derived growth factor (PDGF) receptor (2,4-6), fibroblast growth factor receptor (FGFR) (7) , TrkA receptor (8) (9) (10) , and insulin receptor [for review see (11) ]. The effect of gangliosides on these growth factor receptors has been demonstrated in vitro by exogenous addition of ganglioside (2, 3, 12) and by alteration of the endogenous ganglioside content (13) (14) (15) (16) (17) .
Exogenous addition of GM3 to the culture media of human epidermoid carcinoma KB and A431 cell lines inhibits cell growth, which has been attributed to inhibition of EGFR autophosphorylation (3). Hanai et al. showed that endogenous GM3 levels changed EGFR activity by selecting two clones of A431 cells that contained different amounts of GM3 (13) . Similarly, a mutant chinese hamster ovary cell line with a reversible defect in ganglioside biosynthesis has displayed physiological regulation of the EGFR activity by endogenous gangliosides (14) . Approaches using gene transfection 5
These data indicate that GM3 may act as a physiological modulator of EGFR activity. The mechanism for GM3 inhibition of the EGFR is not understood. The ability of A431 membrane preparations rich in EGFR to bind to GM3 coated plates (18) or to GM3 coated beads (19) suggests a direct interaction with GM3. But, since EGFR was not the only component of the membrane preparations, we cannot rule out the possibility that GM3 also binds to other membrane components, such as a tyrosine specific phosphatase, as suggested by Suarez Pestana et al. (20, 21) . Purified recombinant domains of the EGFR provide a means to determine if GM3 interacts directly with the EGFR and localizes this binding site to the extracellular or ectodomain of EGFR.
7
(Hoefer Pharmacia Biotech, San Francisco, CA) using Towbin buffer (23) for 1hr at a constant current of 200mA. Membranes were blocked using 5% non-fat dried milk (w/v, Sanalac, Hunt-Weller, Fullerton, CA) in PBS (10mM phosphate buffer pH 7.4, 120mM
NaCl, 2.7mM KCl) containing 0.1% Tween 20 (PBST) for 1hr at room temperature.
Primary antibodies were diluted in PBST at the following concentrations: anti-EGFR clone LA22, 1µg/ml; anti-phosphotryosine antibody RC20, 1:2500 (v/v); anti-EGFR P-Y (1086), 0.5µg/ml; Anti-EGFR SC-03, 0.2µg/ml; anti-His tag, 1:5000 (v/v). They were incubated for 1hr with gentle agitation and the membranes were then washed in PBST (1 x 10min and 2 x 5 min). Secondary antibodies, anti-mouse or anti-rabbit peroxidase (Amersham Pharmacia, Piscataway, NJ), were diluted to 1:5000 (v/v) in PBST, incubated for 1hr and washed again in PBST. Chemiluminescent detection was carried out according to the instructions supplied (ECL, Amersham Pharmacia, Piscataway, NJ), and captured on Kodak ML (Kodak, Rochester, NY) autoradiography film. Some blots were stripped by incubation at 50 0 C for 30min in stripping buffer (63mM Tris pH 6.8, 2% SDS w/v, 100mM β-mercaptoethanol), and the membranes washed and reprobed.
Expression of recombinant ECD of the EGFR in insect cells
An EGFR cDNA with a sequence identical to GenBank accession number NM_005228 (National Center for Biotechnology Information) was used as a template for the production of a subclone containing the extracellular domain (ECD). The ECD 8 5'CACCTCGAGGGCGATGGACGGGATCTTAGG3'. The ECD PCR product was inserted into the pBac1 (Novagen, Madison, WI) baculovirus transfer vector using a 5' Stu1 and a 3' Xho1 restriction digestion site. The recombinant vector was subjected to DNA sequencing to confirm that the PCR product did not have any mutations and that the C-terminal His tag was in the correct frame. The vector was then integrated with baculovirus using Novagen's Bac 3000 kit.
Production and purification of recombinant ECD protein
Insect High five cells (Invitrogen, Carlsbad, CA), derived from Trichoplusia ni egg cell homogenates, were grown in monolayer for expression of the ECD. Cells grown to approximately 70% confluency were infected with a 1:30 (v/v) dilution of viral stock.
Large-scale baculovirus infection was carried out in 10 round Falcon 150mm X 25mm (Beckton Dickinson, Franklin Lakes, NJ) tissue culture dishes. A previous report has established that a 3-day incubation is ideal for production of ECD (24) . Following a 3-day incubation, media collected from the infected cells was adjusted to pH 8.5 and ultracentrifuged (1hr x 120,000g) to remove cellular debris. The cleared supernatant containing the ECD was either processed immediately or stored at -20 0 C. All subsequent steps of the purification were carried out in an ice bath or at 4 0 C. Piscataway, NJ) using 15mM ammonium bicarbonate, 10mM NaCl running buffer, and fractions were collected. SDS-PAGE and western blotting was used to assess the location and purity of the ECD in the fractions. Subsequently, the highest quality fractions were pooled, aliquoted, lypholized and stored at -20 0 C.
Deglycosylation of the ECD
The ECD was deglycosylated under native conditions using N-Glycosidase F (Calbiochem, San Diego, CA). Approximately 10U N-Glycosidase F was used to cleave 10µg of purified ECD dissolved in PBS to a concentration of 0.25µg/ml. The equivalent volume of 50% glycerol was added to a control sample. Both samples were incubated for 36hr at 25 0 C. The deglycosylated protein was analyzed by SDS-PAGE and western blotting using the LA22 antibody.
I-EGF binding to the extracellular domain
The binding constants of ECD for EGF in the presence or absence of gangliosides were determined, using the scintillation proximity assay (SPA) developed by Amersham Placid, NY) to yield a specific activity of 5000cpm/pmol and incubated in the reaction using dilutions ranging from 10-500nM, and incubated for 30min at room temperature to achieve equilibrium. In order to determine non-specific binding, 100-fold molar excess of unlabeled EGF was incubated in the reaction mixture. Auger electrons (representing bound EGF) were measured using a Beckman LS6000 SC scintillation counter set to detect the 3 H isotope. In reactions in which gangliosides were present, the gangliosides were resuspended in PBS to a stock concentration of 1mM, sonicated for 10min, and diluted in the reaction to a final concentration of 100µM. The gangliosides were added to the reaction after the ECD but prior to the addition of 125 I-EGF. Data generated from the SPA assay were first converted into standard units of nmol with Microsoft Excel prior to analysis of the curve using a one binding site hyperbola function with Prism (Graphpad Software).
Solid phase ganglioside binding assay
To 
EGFR autophosphorylation assay
A431 membrane preparations in EGFR were prepared as previously described (3).
Gangliosides dissolved in methanol were dried to the bottom of the 10mm x 75mm glass tubes and resuspended in assay buffer (20mM Hepes pH 7.4, 150mM NaCl and 0.05% Triton X100). The EGFR-enriched A431 membrane preparation was added (5ug total protein) and incubated with the gangliosides for 10min at room temperature. EGF (100ng) was added to the reaction and incubated for a further 10min. The assay tubes were then transferred to an ice bath and 50µM ATP (Amersham Pharmacia, Piscataway, incubation on ice, the reaction was quenched by the addition of SDS-PAGE sample buffer, boiled, and analyzed by SDS-PAGE and western blotting using both anti-EGFR P-Y (1086) and anti-phosphotyrosine RC20 antibodies. The results from three independent experiments were quantitated by densitometry using the integrated density function (NIH image 1.62 software) and expressed as percent of EGF-stimulated.
Statistical analysis of the densitometry results was carried out using Prism software (Mann-Whitney test). An intracellular kinase assay kit containing a recombinant EGFR kinase domain was purchased from Stratagene (La Jolla, CA). Except for the addition of ganglioside, the intracellular kinase assay was carried out using RR-src peptide as a substrate similar to that described by Hsu et al. (25) .
Results

Expression and purification of recombinant ECD
In this report we explore the direct interaction of gangliosides with the EGFR by employing highly purified recombinant extracellular domain (ECD) of EGFR. It is generally agreed that the majority of gangliosides are found in the outer leaflet of the membrane. We speculate that they may interact physiologically with the ECD. The ECD contains several regulatory elements required for the normal functioning of the receptor. In addition to ligand binding, the ECD is also responsible for dimerization of the EGFR (24, (26) (27) (28) (29) . GM3 has been shown to inhibit dimerization of the receptor (1), which suggests that GM3 binds at or near a site that regulates dimerization.
To study the possible interaction of GM3 with the EGFR, recombinant ECD was The apparent molecular weight of the purified ECD, as determined by gel electrophoresis, was approximately 89,000. This is greater than the predicted 72,000 of the nascent polypeptide chain and is most likely due to glycosylation. The ECD was deglycosylated by N-Glycosidase F and displayed a M r shift from 89,000 to approximately 72,000 (Fig. 1 D) , consistent with glycosylation of the ECD (26) .
EGF binding to the ECD construct
A scintillation proximity assay (SPA) was employed to determine the effect of gangliosides on EGF binding to the ECD. The binding constant (Kd = 102.1 + 13.4 nM) for the recombinant ECD was similar to previously published results ( Fig. 2 and   24 ,26,31). Neither GM3 nor GM1 had a significant effect on binding of EGF to the ECD (Fig. 2) . Neither the affinity (Kd) for EGF nor the number of EGF binding sites (Bmax) changed statistically in the presence of gangliosides. Moreover, the amount of ECD present as determined by Bmax was in agreement with the amount added, as determined by protein assay.
Direct binding of ECD to gangliosides
Using purified ECD we tested whether the ECD interacts directly with GM3. The ganglioside interaction assay was carried out using an assay similar to that described for the full-length EGFR (18) . The amounts of gangliosides used for coating the plates varied from 10 to 5000pmol (Fig 3 A) . The highest signal was obtained at 500pmol GM3 coating, with a saturated signal at higher concentrations. The ECD demonstrated a strong binding preference for GM3 over GM1 at all ganglioside coating concentrations tested (Fig. 3 A) . Using 500pmol of either GM3 or GM1 for coating, the ECD concentration was then varied from 0.25 to 5µg/ml (Fig. 3 B) . At all concentrations of ECD the signal was specific for GM3 and appeared to saturate at approximately 2.5µg/ml ECD (28nM).
Next we examined which structural determinants on the ganglioside directed this interaction. Different gangliosides were coated on ELISA plates at the same density (500pmol) and tested for ECD binding at 2.5µg/ml ECD. Of the ten gangliosides tested, GM3 revealed the strongest signal and GM2, GM4 and GD3 showed approximately 50% or less binding activity (Fig 3 C ; Table 1 ). No significant binding was detected with GM1, GD1a, GD1b, GT1b, GD2 or GQ1b. Both EGFR-specific antibody (clone LA22, data not shown) and anti-His tag antibody (Fig. 3) gave identical results. To confirm that gangliosides remained coated to the plates during the assay, anti-ganglioside antibodies directed towards GM1 and GM3 were used in place of the LA22 antibody. Equivalent binding of both anti-GM3 and anti-GM1 antibodies were observed, indicating that there was no preferential loss of gangliosides (18) .
EGFR autophosphorylation
The binding data indicate interaction of ECD with GM3, GM2, GD3 and GM4.
To ascertain whether these gangliosides were able to inhibit EGFR autophosphorylation we performed EGFR autophosphorylation assays. 
B). As previously described (3), GM3 inhibited EGF-stimulated autophosphorylation
to background levels. Minimal inhibition was observed for ganglioside GM2, although this was not statistically significant (Table 1) . No inhibition was observed with GD3 even though it appeared to bind ECD second to GM3. In addition, most gangliosides appeared to slightly increase autophosphorylation. Again, this increase was not statistically significant. To further test if ganglioside inhibition of EGFR acts through the ECD, the ability of GM3 to directly inhibit the EGFR kinase was tested on a recombinant EGFR kinase domain. No inhibition of the kinase domain was observed in the presence of GM3 (Fig 4 C) .
The ECD was found to preferentially interact with GM3 over all other gangliosides tested. Subsequently, the gangliosides showing binding activity were also tested for the ability to inhibit full-length EGFR autophosphorylation. The ganglioside structure, binding data, and EGFR autophosphorylation inhibition are summarized in Table 1 . Binding and inhibition of autophosphorylation appear to be specific for the NANALac structure on GM3.
Discussion
We produced the ECD of the EGFR as recombinant protein and demonstrated direct binding of GM3 to this receptor domain. It is generally accepted that gangliosides are asymmetrically distributed on the outer leaflet of the plasma membrane. Placing gangliosides in juxtaposition to the ECD would, therefore, be consistent with the hypothesis that GM3 modulates the EGFR in vivo.
In the series of gangliosides tested for binding, the data showed a high degree of specificity for GM3 and indicated that a single sugar substitution at either the NANA or Gal of GM3 (GD3; GM2) reduced binding by more than 50%. The entire trisaccharride structure of GM3 (NANALac) appears to be important for binding to the ECD. Unsubstituted NANA-Gal structures, as found at the non-reducing terminal of both gangliosides GD1a and GT1b, did not show any binding activity at all. GM4 also contains this NANA-Gal structure with no other sugar groups and appears to weakly bind ECD. GM4 binding to the ECD was similar to substitution of either the NANA or Gal. These observations suggest that all three-carbohydrate moieties of monosialoganglioside GM3 are necessary to interact with the ECD.
The specificity of ECD binding to GM3 was also observed for ganglioside inhibition of full-length EGFR autophosphorylation. GM3 exhibited the highest binding activity and inhibited EGFR autophosphorylation to non-EGF stimulated levels (Table 1) .
No other ganglioside showed any significant inhibition of EGFR autophosphorylation.
Although not statistically significant, gangliosides GD3, GM1, GD1a and GT1b tended to slightly increase, and GM2 slightly decrease, EGFR autophosphorylation. The inability of gangliosides that weakly bind ECD to inhibit EGFR autophosphorylation may suggest that while binding to the ECD may involve all three sugars in GM3, inhibition of autophosphorylation may require an unsubstituted α2,3NANA. This may explain the slight inhibition observed for GM2 and lack of inhibition by GD3. Previous data indicated that chemical modification of NANA on GM3 results in a loss of inhibitory activity (1). Alternatively, the physical properties of gangliosides immobilized on a solid phase as opposed to the aggregate structure in solution may explain the difference between the ganglioside binding and the kinase assay. As the polar head group on gangliosides increase, there is a tendency towards smaller micellar structures in aqueous solutions similar to detergents (32) . It is possible that the more complex gangliosides may have a detergent-like effect on the in vitro EGFR autophosphorylation assay since addition of Triton X-100 has been shown to enhance EGFR autophosphorylation (33).
This suggests that the increased autophosphorylation by gangliosides, other than GM3, may be due to a detergent-like effect and that this effect may mask any inhibition of weakly binding gangliosides GM2, GM4, and GD3. Regardless, a high degree of specificity for GM3 is observed for both binding to the ECD and inhibition of EGFR autophosphorylation.
Our data indicate that the putative GM3 binding site on the ECD is responsible for inhibition of EGFR autophosphorylation. This hypothesis is supported by the finding that the kinase domain alone appears to be unaffected by GM3. Three findings, however, suggest gangliosides may work through additional mechanisms. First, we previously reported that GM3 treated keratinocyte-derived SCC12 cells decreased the number of EGF binding sites even though EGFR protein levels remained constant (34). Our current finding that GM3 does not alter EGF binding to the ECD suggests that the availability of EGFR at the cell surface may be altered in the presence of gangliosides. This implicates GM3 in the cellular distribution of the receptor. This is of great interest since PDGF receptor is apparently localized by GM1 to ganglioside-rich membrane structures (35), broadly referred to as caveolae (36) , lipid rafts (37) , and glycosphingolipid signaling domains (GSD) (38) . Second, ganglioside activation of phosphatase (PTPase) sigma has been shown to dephosphorylate the EGFR. A role for GM3 in the activation of PTPase sigma was clearly shown using PTPase inhibitors, antisense treatment and transfection experiments (20, 21) . It is likely that gangliosides affect a number of protein functions in the membrane, including PTPases and other growth factor receptors (2-11). Third, Li et al. reports that preincubation of fibroblast cells with GD1a elicited a growth factor-like response in the absence of serum or growth factors (39, 40) . GD1a may function through a mechanism other than direct interaction with the EGFR since no binding of the ECD was observed to GD1a. It appears that, in addition to direct binding to the receptor, gangliosides may act by different mechanisms to modulate EGFR signal pathways.
These multiple effects are difficult to simulate in vitro and posses a challenge to determine the exact biochemical events that gangliosides participate in.
In conclusion, we hypothesize that the GM3 binding site on the ECD of the EGFR directly regulates receptor activity. Following ligand binding, the EGFR undergoes dimerization that is required for autophosphorylation and activation of the receptor (24, (26) (27) (28) (29) . The ECD is thought to drive both homo and hetero dimerization of the erb-B family (29) . It has been shown that GM3 interferes with the dimerization of the EGFR (1). The affinity constant for dimerization of the ECD has been reported to be 2.4µM (27) . In this context it is of interest that our calculated Kd for GM3 binding to the ECD is 2µM (approximation from Fig 3A) . This value appears to be in the same range as the Kd for dimerization and suggests that GM3 acts as a physiological competitor for dimerization preventing spontaneous activation of the EGFR in vivo. Efforts are ongoing in our laboratory to investigate how ganglioside binding relates to the modulation of EGFR signaling in the cell. 
Figure Legends
Figure 3
Solid phase ganglioside binding assay detecting ECD interaction with gangliosides.
A. Effect of different ganglioside coating concentrations on the detection of ECD interaction with GM3 (s) or GM1 (v) using 2.5µg/ml ECD probing concentration. B.
Effect of varying the ECD concentration on the assay using 500pmol GM3 (s) or GM1 
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